Clinical
RSSArticles
-
Stenting Nonculprit Lesions After STEMI: Long-Term Data Support Complete Revascularization
Data from the CvLPRIT trial of complete vs. culprit-only percutaneous coronary intervention in ST-segment elevation myocardial infarction (MI) show a significantly lower rate of major adverse cardiovascular events, all-cause mortality, and lower composite MI in the complete revascularization group at a median follow-up of 5.6 years.
-
CNS Agents Emerge as Frontrunners in FDA-Approved Treatments for Low Libido in Women
Low libido is the most common sexual complaint, affecting up to 38.7% of women, with up to 12.3% also reporting significant distress associated with this condition. In the past five years, for the first time in history, there are two Food and Drug Administration-approved medications specifically for treating hypoactive sexual desire disorder in women. Of note, both medications are central nervous system agents.
-
Estrogen Replacement: Is Long Duration of Therapy Good for the Brain?
Longer lifetime exposure to endogenous estrogen and menopausal estrogen replacement were associated with better cognitive status in older adult women. Women who initiated estrogen therapy early (within five years of the onset of menopause) showed higher cognitive test scores than those who started later.
-
Tenaculum Placement Techniques and Effect on Pain
In this randomized controlled trial, there was no difference in pain score with tenaculum placement between the slow method of application and coughing with application (median pain score 44 vs. 32, P = 0.16).
-
What Are the Roles of the Combined Oral Contraceptive Pill and Metformin in the Management of Polycystic Ovary Syndrome?
This systematic review documents the effectiveness of combined oral contraceptive pills in treating hyperandrogenism and irregular menses, and of metformin in addressing the metabolic disturbances in women with polycystic ovary syndrome.
-
Researchers Examine Use of Dichloroacetate in Endometriosis Treatment
The authors of a new scientific paper indicate that dichloroacetate, investigated as a potential cancer treatment, may be effective against endometriosis. Finding a new treatment option would augment current treatment strategies of hormone therapy and surgery, which involve significant side effects and recurrence after treatment.
-
Research Focuses on Medroxyprogesterone Acetate in Cervical Cancer Prevention
Preliminary research suggests that medroxyprogesterone acetate, the active ingredient in the contraceptive injection DMPA, may be effective in preventing cervical cancer.
-
Policy Update Advocates Teen Access to Emergency Contraception
To help prevent unplanned pregnancy among adolescents, the American Academy of Pediatrics has issued an updated policy statement on emergency contraception (EC) to educate providers on use of EC in adolescents, and advocate for expanded access for teens.
-
Investigational Contraceptive Patch Clears FDA Panel Vote
Twirla, an investigational combined hormonal contraceptive patch, is under review by the FDA. In an October 2019 meeting, the patch received a 14 to 1 vote from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee.
-
FDA Approves Liletta IUD for Six Years of Effective Use
The FDA has approved the Liletta levonorgestrel intrauterine device (IUD) for six years of effective use. The 52 mg device, similar in size to the Mirena IUD, was approved for the U.S. in February 2015.